|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's range||31.17 - 31.92|
|52-week range||21.20 - 41.84|
|Beta (5Y monthly)||2.08|
|PE ratio (TTM)||15.86|
|Earnings date||26 Jul 2023 - 31 Jul 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||47.00|
InMode, Johnson & Johnson, Intuitive Surgical and GE HealthCare are included in this Analyst Blog.
CNBC's Jim Cramer predicts a booming bull market for medical devices, with positive earnings reports across the space. INMD, JNJ, ISRG and GEHC can emerge as potential winners.
Have you noticed growth stocks are making a comeback? The Vanguard Growth ETF, which contains heaps of growth stocks, is up 21% this year. If you've been investing in growth stocks for a while you probably remember they started soaring last summer and then lost all those gains by the end of 2022.
It's not easy to find that combination given the current economic conditions, but one that could fit the bill is InMode (NASDAQ: INMD). With U.S. economic growth slowing, many fast-growing businesses have been laying off staff to cut costs after previously overestimating their growth opportunities. InMode, however, is still firing on all cylinders.
Teladoc Health (NYSE: TDOC) and InMode (NASDAQ: INMD) both operate in high-growth industries. Teladoc is a leader in telemedicine. InMode specializes in selling devices in the minimally invasive and non-invasive aesthetics market.
Over the past few years, new investors have learned the hard way that investing in growth stocks can be highly unpredictable. You may remember the Nasdaq Composite, which contains heaps of growth stocks, rose 21% in 2021, only to collapse 33% in 2022. Giant market swings like the one recently experienced may lead you to believe that growth stock investing is an endeavor only suited to Wall Street professionals, but this is not the case.
This company's minimally invasive alternative to liposuction surgery isn't getting the attention it deserves.
The average of price targets set by Wall Street analysts indicates a potential upside of 46% in InMode (INMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What happened The stock of medical aesthetics tech company InMode (NASDAQ: INMD) wasn't looking very pretty on Tuesday. The company published its latest set of quarterly figures, and some investors found them sorely wanting.
Image source: The Motley Fool. InMode (NASDAQ: INMD)Q1 2023 Earnings CallMay 02, 2023, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and welcome to the InMode first quarter 2023 financial results conference call.
InMode (INMD) delivered earnings and revenue surprises of 4% and 0.26%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad (BIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
When you think of healthcare stocks, you may think of steady growth and security. Let's check out three healthcare companies that fit the bill. In fact, if all goes well, Vertex may launch a new CF treatment in the not-too-distant future.
If you've paid any attention to the stock market over the past few years, you know that growth-stock investing can be wildly unpredictable. You probably remember the Nasdaq Composite index, which houses a lot of growth stocks, briefly tanked at the outset of the COVID-19 pandemic in 2020. Assuming your emergency fund is topped off and you have all your bills paid, just $200 is enough to buy one share of each of these top growth stocks.
The consensus price target hints at a 33.7% upside potential for InMode (INMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
It's never too early to start planning for the next bull market. Those days of market gains and optimism will be back. History tells us so -- bull markets always have followed bear markets. So, how should you prepare? By taking advantage of the low prices a down market offers us and buying quality companies that could win over time.
Despite being one of the world's largest, most steadily growing businesses, Amazon's (NASDAQ: AMZN) stock fell by around 40% in the last 12 months, leaving investors looking for alternatives to buy for growth. At the same time, analysts anticipate that lesser-known growth stocks like InMode (NASDAQ: INMD) and Green Thumb Industries (OTC: GTBIF) will see their shares climb by 63% and 152%, respectively, which would mean they'd blow Amazon out of the water.
Teladoc specializes in virtual medical visits and sells its plans to companies and organizations. Teladoc also sells its BetterHelp mental health online consultations directly to consumers. What's weighed on the stock is the fact that Teladoc hasn't yet turned that revenue into profit.
These businesses are at the top of their respective industries, but you wouldn't know it by looking at their stock prices.
The market doesn't always get a growth stock's valuation right, and when it's wrong, there's often an opportunity to make a hearty dollop of dosh -- and it's always good to feel as if you're a step ahead of the market. On that note, two growth stocks look favorably priced right now, and there's good reason to think they'll keep growing in the years ahead. Israeli medical aesthetics company InMode (NASDAQ: INMD) is a stellar investment opportunity thanks to its slightly cheap shares and its finely tuned growth engine.
Wall Street analysts are expecting that 23andMe's (NASDAQ: ME) stock will hit around $5.69 within a year, which means they think it can grow to more than double its current price of $2.61. In 2019, it reported sales of $156.3 million, which means that its compound annual growth rate (CAGR) from 2019 through 2024 would be 31.3%.
Wall Street analysts aren't always right with their predictions about stocks, but they typically have a strong argument for why they think a given outcome is going to happen. On that note, let's evaluate a couple of growth stocks that Wall Street has high hopes for to see if they might be a good fit for your portfolio. When it comes to businesses making medical aesthetics treatments that are alternatives to plastic surgeries and face lifts, InMode (NASDAQ: INMD) is a leader.
Last year, investors learned the hard way that growth stock investing can be unpredictable. The Nasdaq Composite index, which contains heaps of growth stocks, collapsed by 33% in 2022. One recurring theme for bear markets like the one we've experienced is that they've always been temporary.
Take medical technology (or medtech) stocks, for example. Both InMode (NASDAQ: INMD) and Outset Medical (NASDAQ: OM) reported their fourth-quarter results this week. Which is the better medtech stock to buy?